查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178512

黑色素瘤診斷的全球市場 - 產業趨勢與預測(～2030年)

Global Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 438 Pages | 商品交期: 請詢問到貨日

價格

全球黑色素瘤診斷的市場規模，預計2023年～2030年的預測期間記錄7.2％的大幅度的年複合成長率。

推動市場成長的主要原因，是黑色素瘤的盛行率增加，新技術的採用增加，及對實驗室專家來說容易取得。

本報告提供全球黑色素瘤診斷市場調查，市場促進因素和阻礙因素，機會和課題，各市場區隔、地區的市場明細，競爭情形，主要企業簡介等彙整資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

  • PESTEL的模式
  • 波特的五力分析

第5章 流行病學

第6章 產業考察

  • 人口動態趨勢
  • 主要的價格策略
    • 產品創新
    • 消費者意識
    • 廣大的流通網路
    • 跟受歡迎品牌的夥伴關係:各主要企業
    • 其他
  • 主要的病患註冊策略
    • 對創新的診斷產品的客戶需求特定
    • 每階段的特定策略增加
    • 教育和通訊
    • 診斷要求率的提高
  • 廠商的採訪

第7章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第8章 全球黑色素瘤診斷市場:各產品類型

  • 概要
  • 設備
    • 影像設備
    • 切片檢查設備
    • 病理學為基礎的設備
  • 消耗品、配件
    • 套件
    • 探針
    • 試劑
    • 其他的消耗品
  • 其他

第9章 全球黑色素瘤診斷市場:各檢驗類型

  • 概要
  • 影像檢查
    • 超音波
    • MRI
    • 胸部X光
    • 淋巴節閃爍圖術
    • 電腦斷層攝影(CT)掃描
    • 正子放出截面攝影(PET)掃描
    • 其他
  • 切片檢查
    • 光學切片檢查
    • 切除切片檢查
    • 解剖切片檢查
    • 薄片切片檢查
    • 剪票夾切片檢查
    • 其他
  • 免疫組織化學(IHC)檢驗
    • S100蛋白質家庭切片檢查
    • MELAN-A
    • PMEL/PMEL17/SILV/GP100
    • TYROSINASE
    • MITF
    • SM5-1
    • CSPG4/HMW-MAA
  • 生物標記檢驗
    • BRAF變異檢驗
    • NRAS變異檢驗
    • CKIT檢驗
    • 其他
  • 螢光原位雜合反應(FISH)檢驗
  • 比較基因雜合反應(CGH)檢驗
  • 其他

第10章 全球黑色素瘤診斷市場:各終端用戶

  • 概要
  • 醫院
  • 相關實驗室
  • 影像診斷中心
  • 獨立型診斷實驗室
  • 癌症研究機關
  • 其他

第11章 全球黑色素瘤診斷市場:各流通管道

  • 概要
  • 直接競標
  • 零售

第12章 全球黑色素瘤診斷市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 瑞典
    • 波蘭
    • 比利時
    • 瑞士
    • 丹麥
    • 挪威
    • 芬蘭
    • 土耳其
    • 其他歐洲
  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 紐西蘭
    • 印尼
    • 日本
    • 泰國
    • 菲律賓
    • 越南
    • 馬來西亞
    • 韓國
    • 新加坡
    • 台灣
    • 其他亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美
  • 中東、非洲
    • 南非
    • 埃及
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 阿曼
    • 科威特
    • 卡達
    • 巴林
    • 其他中東、非洲

第13章 全球黑色素瘤診斷市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第14章 SWOT分析

第15章 企業簡介

  • ABBOTT
  • ILLUMINA, INC.
  • BIOMERIEUX SA
  • THERMO FISHER SCIENTIFIC INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • AGILENT TECHNOLOGIES, INC.
  • AMLO BIOSCIENCES LIMITED
  • CASTLE BIOSCIENCES INC
  • DAMAE MEDICAL
  • DERMLITE.
  • DERMASENSOR

The global melanoma cancer diagnostics market is projected to register a substantial CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Denmark, Switzerland, Turkey, Sweden, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, UAE, Rest of the Middle East and Africa) Industry Trends and Forecast 2030

Some of the major factors contributing to the growth of the global melanoma cancer diagnostics market are:

Increase in prevalence of melanoma cancer

Rise in adoption of new technologies and easy accessibility for laboratory professionals

Market Players:

Some of the major players operating in the global melanoma cancer diagnostics market are:

Nanostring

Thermo Fisher Scientific Inc.

Quest Diagnostics Incorporated

Agilent Technologies, Inc

Qiagen, Inivata Ltd

F. Hoffman-La Roche Ltd

Abbott

AMLo Biosciences Limited

Myriad Genetics Inc.

Castle Biosciences

DermTech

Michael Diagnostics Ltd

Damae Medical

Skin Analytics

DermLite

DermaSensor

Skyline Dx

Neracare GmbH

VERISKIN INC.

Illumina Inc

bioMerieux SA

TABLE OF CONTENTS

1 INTRODUCTION 49

  • 1.1 OBJECTIVES OF THE STUDY 49
  • 1.2 MARKET DEFINITION 49
  • 1.3 OVERVIEW OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET 49
  • 1.4 LIMITATIONS 51
  • 1.5 MARKETS COVERED 51

2 MARKET SEGMENTATION 54

  • 2.1 MARKETS COVERED 54
  • 2.2 GEOGRAPHICAL SCOPE 55
  • 2.3 YEARS CONSIDERED FOR THE STUDY 56
  • 2.4 CURRENCY AND PRICING 56
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 57
  • 2.6 MULTIVARIATE MODELLING 61
  • 2.7 PRODUCT TYPE LIFELINE CURVE 61
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
  • 2.9 DBMR MARKET POSITION GRID 63
  • 2.10 MARKET END USER COVERAGE GRID 64
  • 2.11 VENDOR SHARE ANALYSIS 65
  • 2.12 SECONDARY SOURCES 66
  • 2.13 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

  • 4.1 PESTEL'S MODEL 72
  • 4.2 PORTER'S FIVE FORCES MODEL 73

5 EPIDEMIOLOGY 74

6 INDUSTRY INSIGHTS 75

  • 6.1 DEMOGRAPHIC TRENDS 75
  • 6.2 KEY PRICING STRATEGIES 76
    • 6.2.1 PRODUCT INNOVATION 76
    • 6.2.2 CONSUMER AWARNESS 76
    • 6.2.3 A VAST NETWORK OF DISTRIBUTION 76
    • 6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS 77
    • 6.2.5 OTHERS 77
  • 6.3 KEY PATIENT ENROLLMENT STRATEGIES 77
    • 6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS 77
    • 6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP 77
    • 6.3.3 EDUCATE AND COMMUNICATE 78
    • 6.3.4 IMPROVING DIAGNOSIS SEEKING RATE 78
  • 6.4 INTERVIEWS WITH MANUFACTURING COMPANIES 78

7 MARKET OVERVIEW 80

  • 7.1 DRIVERS 82
    • 7.1.1 GROWING PREVALENCE OF MELANOMA CANCER 82
    • 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 83
    • 7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS 84
    • 7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER 85
  • 7.2 RESTRAINTS 85
    • 7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 85
    • 7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS 86
  • 7.3 OPPORTUNITIES 86
    • 7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT 86
    • 7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS 87
    • 7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 88
    • 7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 88
  • 7.4 CHALLENGES 89
    • 7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS 89
    • 7.4.2 RADIATION RISKS FROM IMAGING TESTS 89

8 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

  • 8.1 OVERVIEW 91
  • 8.2 INSTRUMENTS 94
    • 8.2.1 IMAGING INSTRUMENTS 95
      • 8.2.1.1 ULTRASOUND SYSTEMS 95
      • 8.2.1.2 MRI SYSTEMS 95
      • 8.2.1.3 CT SYSTEMS 95
      • 8.2.1.4 OTHERS 96
    • 8.2.2 BIOPSY INSTRUMENTS 96
    • 8.2.3 PATHOLOGY-BASED INSTRUMENTS 96
      • 8.2.3.1 PCR INSTRUMENTS 96
      • 8.2.3.2 CELL PROCESSORS 96
      • 8.2.3.3 SLIDE STAINING SYSTEMS 96
      • 8.2.3.4 TISSUE PROCESSING SYSTEMS 97
      • 8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS 97
  • 8.3 CONSUMABLES & ACCESSORIES 97
    • 8.3.1 KITS 98
      • 8.3.1.1 PCR KITS 98
      • 8.3.1.2 NUCLEIC ACID ISOLATION KITS 98
      • 8.3.1.3 DNA POLYMERASE KITS 98
      • 8.3.1.4 OTHERS 99
    • 8.3.2 PROBES 99
      • 8.3.2.1 Q FISH 99
      • 8.3.2.2 FLOW FISH 99
      • 8.3.2.3 OTHERS 99
    • 8.3.3 REAGENTS 99
      • 8.3.3.1 ASSAYS 100
      • 8.3.3.2 BUFFERS 100
      • 8.3.3.3 PRIMERS 100
      • 8.3.3.4 OTHERS 100
    • 8.3.4 OTHER CONSUMABLES 100
  • 8.4 OTHERS 100

9 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE 102

  • 9.1 OVERVIEW 103
  • 9.2 IMAGING TEST 106
    • 9.2.1 ULTRASOUND 107
    • 9.2.2 MRI 107
    • 9.2.3 CHEST X-RAY 107
    • 9.2.4 LYMPHOSCINTIGRAPHY 108
    • 9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN 108
    • 9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 108
    • 9.2.7 OTHERS 108
  • 9.3 BIOPSY 108
    • 9.3.1 OPTICAL BIOPSY 109
    • 9.3.2 EXCISIONAL BIOPSY 109
    • 9.3.3 INCISIONAL BIOPSY 109
    • 9.3.4 SHAVE BIOPSY 110
    • 9.3.5 PUNCH BIOPSY 110
    • 9.3.6 OTHERS 110
  • 9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS 110
    • 9.4.1 S100 PROTEIN FAMILY BIOPSY 111
    • 9.4.2 MELAN-A 111
    • 9.4.3 PMEL/PMEL17/SILV/GP100 111
    • 9.4.4 TYROSINASE 111
    • 9.4.5 MITF 111
    • 9.4.6 SM5-1 111
    • 9.4.7 CSPG4/HMW-MAA 111
  • 9.5 BIOMARKER TEST 112
    • 9.5.1 BRAF MUTATION TEST 113
    • 9.5.2 NRAS MUTATION TEST 113
    • 9.5.3 CKIT TEST 113
    • 9.5.4 OTHERS 113
  • 9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS 113
  • 9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS 114
  • 9.8 OTHERS 115

10 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER 116

  • 10.1 OVERVIEW 117
  • 10.2 HOSPITALS 120
  • 10.3 ASSOCIATED LABS 121
  • 10.4 DIAGNOSTIC IMAGING CENTERS 121
  • 10.5 INDEPENDENT DIAGNOSTIC LABORATORIES 122
  • 10.6 CANCER RESEARCH INSTITUTES 123
  • 10.7 OTHERS 124

11 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 125

  • 11.1 OVERVIEW 126
  • 11.2 DIRECT TENDER 129
  • 11.3 RETAIL SALES 129

12 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION 131

  • 12.1 OVERVIEW 132
  • 12.2 NORTH AMERICA 137
    • 12.2.1 U.S. 147
    • 12.2.2 CANADA 152
    • 12.2.3 MEXICO 157
  • 12.3 EUROPE 162
    • 12.3.1 GERMANY 172
    • 12.3.2 U.K. 177
    • 12.3.3 FRANCE 182
    • 12.3.4 ITALY 187
    • 12.3.5 RUSSIA 192
    • 12.3.6 NETHERLANDS 197
    • 12.3.7 SPAIN 202
    • 12.3.8 SWEDEN 207
    • 12.3.9 POLAND 212
    • 12.3.10 BELGIUM 217
    • 12.3.11 SWITZERLAND 222
    • 12.3.12 DENMARK 227
    • 12.3.13 NORWAY 232
    • 12.3.14 FINLAND 237
    • 12.3.15 TURKEY 242
    • 12.3.16 REST OF EUROPE 247
  • 12.4 ASIA-PACIFIC 248
    • 12.4.1 AUSTRALIA 258
    • 12.4.2 CHINA 263
    • 12.4.3 INDIA 268
    • 12.4.4 NEW ZEALAND 273
    • 12.4.5 INDONESIA 278
    • 12.4.6 JAPAN 283
    • 12.4.7 THAILAND 288
    • 12.4.8 PHILIPPINES 293
    • 12.4.9 VIETNAM 298
    • 12.4.10 MALAYSIA 303
    • 12.4.11 SOUTH KOREA 308
    • 12.4.12 SINGAPORE 313
    • 12.4.13 TAIWAN 318
    • 12.4.14 REST OF ASIA PACIFIC 323
  • 12.5 SOUTH AMERICA 324
    • 12.5.1 BRAZIL 334
    • 12.5.2 ARGENTINA 339
    • 12.5.3 REST OF SOUTH AMERICA 344
  • 12.6 MIDDLE EAST AND AFRICA 345
    • 12.6.1 SOUTH AFRICA 355
    • 12.6.2 EGYPT 360
    • 12.6.3 SAUDI ARABIA 365
    • 12.6.4 U.A.E. 370
    • 12.6.5 OMAN 375
    • 12.6.6 KUWAIT 380
    • 12.6.7 QATAR 385
    • 12.6.8 BAHARAIN 390
    • 12.6.9 REST OF MIDDLE EAST AND AFRICA 395

13 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 396

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 396
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 397
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 398
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 399

14 SWOT ANALYSIS 400

15 COMPANY PROFILE 401

  • 15.1 ABBOTT 401
    • 15.1.1 COMPANY SNAPSHOT 401
    • 15.1.2 REVENUE ANALYSIS 401
    • 15.1.3 COMPANY SHARE ANALYSIS 402
    • 15.1.4 PRODUCT PORTFOLIO 402
    • 15.1.5 RECENT DEVELOPMENTS 402
  • 15.2 ILLUMINA, INC. 403
    • 15.2.1 COMPANY SNAPSHOT 403
    • 15.2.2 REVENUE ANALYSIS 403
    • 15.2.3 COMPANY SHARE ANALYSIS 404
    • 15.2.4 PRODUCT PORTFOLIO 404
    • 15.2.5 RECENT DEVELOPMENT 404
  • 15.3 BIOMERIEUX SA 405
    • 15.3.1 COMPANY SNAPSHOT 405
    • 15.3.2 REVENUE ANALYSIS 405
    • 15.3.3 COMPANY SHARE ANALYSIS 406
    • 15.3.4 PRODUCT PORTFOLIO 406
    • 15.3.5 RECENT DEVELOPMENTS 406
  • 15.4 THERMO FISHER SCIENTIFIC INC. 407
    • 15.4.1 COMPANY SNAPSHOT 407
    • 15.4.2 REVENUE ANALYSIS 407
    • 15.4.3 COMPANY SHARE ANALYSIS 408
    • 15.4.4 PRODUCT PORTFOLIO 408
    • 15.4.5 RECENT DEVELOPMENT 408
  • 15.5 F. HOFFMANN-LA ROCHE LTD. 409
    • 15.5.1 COMPANY SNAPSHOT 409
    • 15.5.2 REVENUE ANALYSIS 409
    • 15.5.3 COMPANY SHARE ANALYSIS 410
    • 15.5.4 PRODUCT PORTFOLIO 410
    • 15.5.5 RECENT DEVELOPMENT 410
  • 15.6 AGILENT TECHNOLOGIES, INC. 411
    • 15.6.1 COMPANY PROFILE 411
    • 15.6.2 REVENUE ANALYSIS 411
    • 15.6.3 PRODUCT PORTFOLIO 412
    • 15.6.4 RECENT DEVELOPMENT 412
  • 15.7 AMLO BIOSCIENCES LIMITED 413
    • 15.7.1 COMPANY PROFILE 413
    • 15.7.2 PRODUCT PORTFOLIO 413
    • 15.7.3 RECENT DEVELOPMENT 413
  • 15.8 CASTLE BIOSCIENCES INC 414
    • 15.8.1 COMPANY SNAPSHOT 414
    • 15.8.2 REVENUE ANALYSIS 414
    • 15.8.3 PRODUCT PORTFOLIO 415
    • 15.8.4 RECENT DEVELOPMENT 415
  • 15.9 DAMAE MEDICAL 416
    • 15.9.1 COMPANY PROFILE 416
    • 15.9.2 PRODUCT PORTFOLIO 416
    • 15.9.3 RECENT DEVELOPMENT 416
  • 15.10 DERMLITE. 417
    • 15.10.1 COMPANY PROFILE 417
    • 15.10.2 PRODUCT PORTFOLIO 417
    • 15.10.3 RECENT DEVELOPMENTS 417
  • 15.11 DERMASENSOR 418
    • 15.11.1 COMPANY PROFILE 418
    • 15.11.2 PRODUCT PORTFOLIO 418
    • 15.11.3 RECENT DEVELOPMENT 418
  • 15.12 DERMTECH 419
    • 15.12.1 COMPANY SNAPSHOT 419
    • 15.12.2 REVENUE ANALYSIS 419
    • 15.12.3 PRODUCT PORTFOLIO 420
    • 15.12.4 RECENT DEVELOPMENT 420
  • 15.13 INIVATA LTD. 421
    • 15.13.1 COMPANY PROFILE 421
    • 15.13.2 PRODUCT PORTFOLIO 421
    • 15.13.3 RECENT DEVELOPMENT 421
  • 15.14 MICHAEL DIAGNOSTICS LTD 422
    • 15.14.1 COMPANY SNAPSHOT 422
    • 15.14.2 PRODUCT PORTFOLIO 422
    • 15.14.3 RECENT DEVELOPMENT 422
  • 15.15 MYRIAD GENETICS, INC. 423
    • 15.15.1 COMPANY SNAPSHOT 423
    • 15.15.2 REVENUE ANALYSIS 423
    • 15.15.3 PRODUCT PORTFOLIO 424
    • 15.15.4 RECENT DEVELOPMENT 424
  • 15.16 NANOSTRING 425
    • 15.16.1 COMPANY SNAPSHOT 425
    • 15.16.2 REVENUE ANALYSIS 425
    • 15.16.3 PRODUCT PORTFOLIO 426
    • 15.16.4 RECENT DEVELOPMENT 426
  • 15.17 NERACARE GMBH 427
    • 15.17.1 COMPANY PROFILE 427
    • 15.17.2 PRODUCT PORTFOLIO 427
    • 15.17.3 RECENT DEVELOPMENT 427
  • 15.18 SKIN ANALYTICS 428
    • 15.18.1 COMPANY PROFILE 428
    • 15.18.2 PRODUCT PORTFOLIO 428
    • 15.18.3 RECENT DEVELOPMENT 428
  • 15.19 SKYLINEDX 429
    • 15.19.1 COMPANY PROFILE 429
    • 15.19.2 PRODUCT PORTFOLIO 429
    • 15.19.3 RECENT DEVELOPMENTS 429
  • 15.20 VERISKIN INC. 430
    • 15.20.1 COMPANY PROFILE 430
    • 15.20.2 PRODUCT PORTFOLIO 430
    • 15.20.3 RECENT DEVELOPMENTS 430
  • 15.21 QIAGEN 431
    • 15.21.1 COMPANY SNAPSHOT 431
    • 15.21.2 REVENUE ANALYSIS 431
    • 15.21.3 PRODUCT PORTFOLIO 432
    • 15.21.4 RECENT DEVELOPMENT 432
  • 15.22 QUEST DIAGNOSTICS INCORPORATED (2022) 433
    • 15.22.1 COMPANY SNAPSHOT 433
    • 15.22.2 REVENUE ANALYSIS 433
    • 15.22.3 PRODUCT PORTFOLIO 434
    • 15.22.4 RECENT DEVELOPMENTS 434

16 QUESTIONNAIRE 435

17 RELATED REPORTS 438

LIST OF FIGURES

  • FIGURE 1 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION 54
  • FIGURE 2 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 57
  • FIGURE 3 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 58
  • FIGURE 4 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 59
  • FIGURE 5 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 59
  • FIGURE 6 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 62
  • FIGURE 7 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 63
  • FIGURE 8 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 64
  • FIGURE 9 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 65
  • FIGURE 10 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION 68
  • FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 69
  • FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030 69
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 70
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR MELANOMA CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 71
  • FIGURE 15 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020 75
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET 81
  • FIGURE 17 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES 83
  • FIGURE 18 AGEING EUROPE POPULATION (IN MILLION) 84
  • FIGURE 19 ESTIMATED LIFETIME CARE SPENDING 87
  • FIGURE 20 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 91
  • FIGURE 21 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 92
  • FIGURE 22 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 92
  • FIGURE 23 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 93
  • FIGURE 24 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 103
  • FIGURE 25 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 104
  • FIGURE 26 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 104
  • FIGURE 27 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 105
  • FIGURE 28 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022 117
  • FIGURE 29 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 118
  • FIGURE 30 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 118
  • FIGURE 31 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 119
  • FIGURE 32 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 126
  • FIGURE 33 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 127
  • FIGURE 34 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 127
  • FIGURE 35 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
  • FIGURE 36 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 133
  • FIGURE 37 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2022) 134
  • FIGURE 38 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 134
  • FIGURE 39 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 135
  • FIGURE 40 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023 & 2030) 135
  • FIGURE 41 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 138
  • FIGURE 42 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 139
  • FIGURE 43 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 139
  • FIGURE 44 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 140
  • FIGURE 45 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 140
  • FIGURE 46 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 163
  • FIGURE 47 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 164
  • FIGURE 48 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 164
  • FIGURE 49 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 165
  • FIGURE 50 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 165
  • FIGURE 51 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 249
  • FIGURE 52 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 250
  • FIGURE 53 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 250
  • FIGURE 54 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 251
  • FIGURE 55 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 251
  • FIGURE 56 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 325
  • FIGURE 57 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 326
  • FIGURE 58 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 326
  • FIGURE 59 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 327
  • FIGURE 60 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 327
  • FIGURE 61 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 346
  • FIGURE 62 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 347
  • FIGURE 63 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 347
  • FIGURE 64 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 348
  • FIGURE 65 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 348
  • FIGURE 66 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 396
  • FIGURE 67 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 397
  • FIGURE 68 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 398
  • FIGURE 69 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 399